Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNT9465
- Development stage
- Unknown
- Lead developer
- Syntara
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
SNT9465 (also known as SNT-9465) is a topical, small molecule pan-lysyl oxidase (pan-LOX) inhibitor developed by Syntara Limited for the treatment of hypertrophic scarring. By inhibiting the lysyl oxidase enzyme family (LOX, LOXL1-4), the drug prevents the excessive cross-linking of collagen fibers that leads to the formation of thick, raised scars. SNT9465 is currently being investigated in a Phase 1b split-scar clinical trial in adults with hypertrophic sternotomy scars to evaluate its safety, target engagement, and efficacy in reducing scar severity. Syntara positions SNT9465 as a potential first-in-class pharmacological treatment for hypertrophic scarring, with plans to file an FDA Investigational New Drug (IND) application following Phase 1b results.
- Other names
- SNT9465SNT-9465SNT 9465
02
Targets
LOXL4 (Lysyl oxidase homolog 4)LOXL3 (Lysyl oxidase-like protein 3)LOXL1 (Lysyl oxidase-like protein 1)15-LOX (Lysyl Oxidase)
Beyond the preview
Go deeper on SNT9465.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNT9465.